Ana M Arance (Ana Arance Fernandez, Ana Arance)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Clinical Practice

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodriguez Abreu, Valentina Boni, Lynn M Schuchter, Maria Gonzales Cao, Ana M Arance, Wei Wei, Apar Kishor Ganti, Ralph J Hauke, Alfonso Berrocal, Nicholas O Iannotti, Frank J Hsu, Harriet M Kluger
A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ines Pires daSilva, Tasnia Ahmed, Jennifer Leigh McQuade, Caroline A Nebhan, John J Park, Judith M Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K Oberoi, Selma Ugurel, Lauren E Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L Smith, Richard A Scolyer, Ana M Arance, Lisa Pickering, James M G Larkin, Paul C Lorigan, Christian U Blank, Dirk Schadendorf, Michael A Davies, Matteo S Carlino, Douglas B Johnson, Georgina V Long, Serigne N Lô, Alexander M Menzies
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (10) (2022)
Aleix Prat, Luis G Paz-Ares, Manel Juan, Enriqueta Felip Font, Elena Garralda, Blanca Gonzalez-Farre, Ana M Arance, Juan Martín-Liberal, Joaquín Gavilá, Ana López-González, Juan Miguel Cejalvo, Yann Izarzugaza, Kepa Amillano, Javier García Corbacho, Cristina Saura, Fabricio Racca, Cinta Hierro, Esther Sanfeliu, Xavier Gonzalez, Jordi Canes, Guillermo Villacampa, Fernando Salvador, Tomás Pascual, Ricard Mesía, Andres Cervantes, Josep Tabernero
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future oncology (London, England) (2022)
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana M Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo Antonio Ascierto
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo Antonio Ascierto, Paul D Nathan, Piotr Lukasz Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandala, Paul C Lorigan, Pier Francesco Ferrucci, Jean-Jacques Grob, Nicolas Meyer, Helen J Gogas, Daniil Stroyakovskiy, Ana M Arance, Jan C Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (13) (2022)
Ana M Arance, Luis de la Cruz Merino, Teresa M Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Marquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Muhammad A Khattak, Catalin Mihalcioiu, Sekwon Jang, C Lance Cowey, Alan D Smith, Natalyn Hawk, Ke Chen, Scott J Diede, Clemens Krepler, Georgina V Long
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paolo Antonio Ascierto, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen J Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana M Arance, Adriana García, Llúcia Alós, Cristina Teixidó
Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. Exploration of targeted anti-tumor therapy 1 (2) (2020)